September 27, 2023

Dear Senator:

We sincerely thank you and your colleagues for recognizing and decisively responding to the challenges of Alzheimer’s disease and other forms of dementia (including vascular, Lewy body dementia, frontotemporal degeneration, and Creutzfeldt-Jakob disease). Congressional determination to make dementia a national priority has been evident, powerful, and effective. From passage of the National Alzheimer’s Project Act to historic funding increases for research, and legislation that improves quality of life for those facing dementia while strengthening the scientific enterprise, Congress has recognized overcoming dementia as a budgetary necessity, an economic priority, and a health and moral imperative. In furtherance of this Congressionally established national priority, we ask you to become a co-sponsor of the bicameral, bipartisan Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act (S.2379 / H.R.4752).

The CHANGE Act strengthens dementia detection, in turn catalyzing improved care, promoting health equity, and accelerating science to prevent, effectively treat, and eventually cure Alzheimer’s disease and related forms of dementia. Specifically, the CHANGE Act directs the Centers of Medicare and Medicaid Services (CMS) to require professionals providing the Medicare Annual Wellness Visits (AWV) and Welcome to Medicare Visits (WMV) to use cognitive impairment detection tools identified by the National Institute on Aging (NIA). Use of these tools will allow clinicians to better detect mild cognitive impairment and other early symptoms of Alzheimer’s disease and related forms of dementia.

CMS currently encourages, but does not require, providers to use a brief validated structured cognitive assessment tool. Consequently, many providers use “direct observation,” rather than a validated tool, to assess patients’ cognitive health. We know of no authoritative source or evidence-based rationale supporting use of direct observation as a means of adequately detecting early cognitive impairment. In fact, direct observation is the least useful and least appropriate tool, all too often contributing to under-diagnosis, delayed diagnosis, misdiagnosis, and non-disclosure of diagnosis. Such failure carries extraordinary potential to harm any patient and to deepen existing health disparities for women, people of color, rural populations, economically disadvantaged people, and
adults with pre-existing cognitive conditions (such as autism, Down syndrome, intellectual disability, severe psychiatric diagnoses, etc.). Recent studies showed that among patients aged 70 years or older, seen in primary care settings, cognitive impairment goes unrecognized in more than 50% of cases. Among older Latino adults, approximately 40% have undiagnosed cognitive symptoms for three years or more. Underutilization of validated assessment tools delays detection and diagnosis, resulting in decreased opportunities for people to access timely treatment options, including clinical research participation.

Providers need not rely on direct observation alone. Free, easy-to-use, validated assessment tools exist, and a number of these tools are listed on the NIA website. The CHANGE Act requires Medicare to equip providers to use the NIA tools, which will improve care for millions of families currently facing Alzheimer’s disease. When people receive a timely and accurate diagnosis, they have improved opportunities to make informed and productive medical, financial, legal, and spiritual choices to strengthen both their own quality of life and that of their family caregivers.

The CHANGE Act would help providers detect Alzheimer’s sooner, which is increasingly important in light of new FDA-approved and Medicare-covered therapies that are for use in early-stage Alzheimer’s disease and as Medicare prepares to launch its nationwide comprehensive dementia care model. As research increasingly focuses on intervening at the earliest point in the disease trajectory, shortcomings in disease detection impede progress toward breakthrough therapies. The CHANGE Act strengthens providers’ readiness to conduct timely and accurate cognitive assessment, convey diagnosis, and document this in a patient’s record.

The CHANGE Act comes at a time of deepening urgency and expanding opportunity. While the need never has been greater, Congress and federal agencies are taking unprecedented action to build comprehensive, integrated, and transformative solutions.

Please contact Dana Richter (dana_richter@capito.senate.gov) with Senator Capito or Amy Brown (amy_brown@stabenow.senate.gov) with Senator Stabenow regarding any questions about or to become a CHANGE Act co-sponsor.

Thank you for considering our views and for your commitment to overcoming Alzheimer’s disease and other forms of dementia. For any questions or additional information about this or other policy issues, please contact Ian Kremer, executive director of Leaders Engaged on Alzheimer's Disease (the LEAD Coalition), ikremer@leadcoalition.org.
Sincerely,

Acadia Pharmaceuticals Inc
ACCSES – The Voice of Disability Service Providers
Activists Against Alzheimer’s Network
ADvancing States
African American Network Against Alzheimer's
AgenerBio
AgeWell Collaboratory of Drexel University
Neelum T. Aggarwal, MD (Rush University Medical Center*)
Aging Life Care Association®
Paul S. Aisen, MD (Keck School of Medicine of USC, Alzheimer’s Therapeutic Research Institute*)
Benedict C. Albensi, PhD, BCMAS, CRQM (Nova Southeastern University*)
Ricardo F. Allegri MD, PhD (School of Medicine, Universidad de Buenos Aires*)
Alliance for Aging Research
Alliance for Patient Access
Michael L. Alosco, PhD (Alzheimer’s Disease Research Center, Boston University Chobanian & Avedisian School of Medicine*)
Alzheimer’s Association
Alzheimer’s Disease Resource Center, Inc. (ADRC)
Alzheimer’s Drug Discovery Foundation
Alzheimer’s Foundation of America
Alzheimer’s Impact Movement (AIM)
Alzheimer’s Los Angeles
Alzheimer’s New Jersey
Alzheimer’s Orange County
Alzheimer’s San Diego
Alzheon
Takashi Amano, PhD, MSW (Rutgers University Newark*)
AMDA – The Society for Post-Acute and Long-Term Care Medicine
Halima Amjad, MD, PhD, MPH (Johns Hopkins University School of Medicine*)
American Academy of Neurology
American Association for Geriatric Psychiatry
American Brain Coalition
American Federation for Aging Research (AFAR)
American Medical Women’s Association
American Society of Consultant Pharmacists (ASCP)
American Society on Aging
Brian S. Appleby, M.D. (Case Western Reserve University School of Medicine*)
Argentum | Expanding Senior Living
Association of State and Territorial Health Officials (ASTHO)
Athira Pharma, Inc.
Rhoda Au, Ph.D. (Boston University Chobanian & Avedisian School of Medicine and Public Health*)
Autistic Women & Nonbinary Network — AWN
The Balm In Gilead, Inc.
Ann D. Cohen, PhD (Department of Psychiatry, University of Pittsburgh, School of Medicine*)
Sharon Cohen, MD, FRCPC (Toronto Memory Program*)
Corium
Tara A. Cortes PhD, RN, FAAN, FGSA (NYU Rory Meyers College of Nursing, The Hartford Institute for Geriatric Nursing*)
Creutzfeldt-Jakob Disease Foundation
Jeffrey Cummings, MD, ScD (University of Nevada Las Vegas*)
CurePSP
Kirk R. Daffner MD, FAAN (Department of Neurology, Harvard Medical School*)
Walter Dawson, Dphil (Oregon Health & Science University*)
Steven T. DeKosky, MD, FACP, FANA, FAAN (University of Floriday College of Medicine*)
Dementia Alliance International
Dementia Alliance of North Carolina
DigiCARE Realized Inc.
Disability Rights California
Elizabeth Disbrow, PhD (LSU Health Shreveport Center for Brain Health*)
Diverse Elders Coalition
Michael C Donohue, PhD (Keck School of Medicine of USC *)
Eisai, Inc.
Eli Lilly and Company
The Emory Goizueta Alzheimer's Disease Research Center
Fayron Epps, PhD, RN, FGSA, FAAN (Emory University, Nell Hodgson Woodruff School of Nursing*)
Gary Epstein-Lubow, MD (Alpert Medical School of Brown University & Brown University School of Public Health*)
Faith United Against Alzheimer's Coalition
Family Caregiver Alliance
D. Luke Fischer, MD, PhD (Weill Institute for Neurosciences, University of California, San Francisco*)
Brent P. Forester, MD, MSc (Tufts University School of Medicine*)
Richard H. Fortinsky, PhD (UConn Center on Aging, University of Connecticut School of Medicine*)
Seth A. Gale, M.D. (Brigham and Women's Hospital, Harvard Medical School*)
Michela Gallagher, PhD (Johns Hopkins University School of Medicine*)
Sam Gandy, MD, PhD (Icahn School of Medicine at Mount Sinai*)
Joseph E. Gaugler, PhD (School of Public Health, University of Minnesota*)
David S. Geldmacher, MD, FACP (University of Alabama at Birmingham School of Medicine*)
Genentech, Inc.
Genetic Alliance
Georgetown University Medical Center Memory Disorders Program
Gerontological Advanced Practice Nurses Association
David B. Reuben, MD (David Geffen School of Medicine at UCLA*)
The Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins Medicine
Roche Diagnostics Corporation
Emily Rogalski, PhD (University of Chicago*)
Gary J. Romano, M.D., Ph.D. (Lewis Katz School of Medicine at Temple University*)
Quincy Miles Samus, PhD, MS (Johns Hopkins School of Medicine*)
Nihal Satyadev, MD, MPH (Mayo Clinic*)
Andrew J. Saykin, PsyD, ABCN (Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine*)
Suzanne Schindler MD, PhD (Washington University School of Medicine, Department of Neurology*)
Julie A. Schneider, MD, MS (Rush Alzheimer's Disease Center, Rush University*)
Michael Schöll PhD (University of Gothenburg*)
Second Wind Dreams, Inc./ Virtual Dementia Tour
Dennis J. Selkoe, MD (Brigham and Women’s Hospital, Harvard Medical School*)
Saurabh Sharma, MD (Georgetown University Memory Disorders Program*)
Leslie M. Shaw, PhD (Perelman School of Medicine, University of Pennsylvania*)
Gary Small, MD (Hackensack Meridian School of Medicine*)
Amanda G. Smith, M.D. (USF Health Byrd Alzheimer's Institute*)
Peter J. Snyder, Ph.D. (Albert Medical School of Brown University*)
Society for Women's Health Research
Reisa A. Sperling, MD, MMSc (Center for Alzheimer Research and Treatment, Harvard Medical School*)
Alan B. Stevens, PhD (Baylor Scott & White Health, Center for Healthcare Policy*)
Donald Sullivan, MD, MA, MCR (Oregon Health and Science University*)
Russell H. Swerdlow, M.D. (University of Kansas School of Medicine*)
Malú Gámez Tansey, Ph.D. (College of Medicine, University of Florida*)
Rudolph Tanzi, PhD (Department of Neurology, MGH/Harvard Medical School*)
Pierre N. Tariot, MD (University of Arizona College of Medicine*)
Carmela Tartaglia, M.D., FRCPC (Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto*)
Texas Rare Alliance
The Association for Frontotemporal Degeneration
The Michael J. Fox Foundation for Parkinson’s Research

Debra F Tomasino, MA, CDP (Yale University, School of Medicine*)

Trellis/ACT on Alzheimer’s

Geoffrey Tremont, Ph.D., ABPP-CN (Alpert Medical School of Brown University*)

Elena Tsoy, PhD (Department of Neurology, University of California, San Francisco*)

R. Scott Turner, MD, PhD (Georgetown University Memory Disorders Program*)

UCLA Mary S. Easton Center for Alzheimer’s Research and Care, David Geffen School of Medicine

University of Minnesota Center for Healthy Aging and Innovation (CHAI)

University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE)

UsAgainstAlzheimer’s, LEAD Coalition co-convener

USAging

Ipsit Vahia, MD (Mclean Hospital, Harvard Medical School*)

Lawren Vandervrede, MD/PhD (University of California, San Francisco Memory and Aging Center*)

Christopher H. van Dyck, MD (Alzheimer’s Disease Research Center, Yale School of Medicine*)

VeteransAgainstAlzheimer’s

Anand Viswanathan, MD, PhD (Massachusetts General Hospital and Alzheimer’s Disease Research Center*)

Voices of Alzheimer’s

Stella L. Volpe, PhD, RDN, ACSM-CEP, FACSM (Virginia Tech*)

Volunteers of America, LEAD Coalition co-convener

Keith Vossel, MD, MSc (Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine at UCLA*)

Victoria Walker MD, FAAFP, CMD (Sanford School of Medicine, University of South Dakota*)

Qing Wang Ph.D. (Washington University in St. Louis, School of Medicine*)

Carol J. Whitlatch, PhD (Benjamin Rose Institute on Aging*)

Nancy Wilson, MA LCSW (Baylor College of Medicine*)

Jennifer Wolff, PhD (Johns Hopkins Bloomberg School of Public Health*)

David A. Wolk, MD, FAAN (Alzheimer’s Disease Research Center, Perelman School of Medicine at the University of Pennsylvania*)

Benjamin Wolozin, M.D., Ph.D. (Boston University Chobanian & Avedisian School of Medicine*)

WomenAgainstAlzheimer’s

Mia Yang MD MS (Wake Forest School of Medicine, Department of Internal Medicine - Section on Geriatric Medicine & Gerontology*)

Julie M. Zissimopoulos, Ph.D. (University of Southern California, Price School of Public Policy*)
* Affiliations of individual researchers are for identification purposes only and do not necessarily represent the endorsement of affiliated institutions.

---


ii [https://www.nia.nih.gov/health/alzheimers-dementia-resources-for-professionals](https://www.nia.nih.gov/health/alzheimers-dementia-resources-for-professionals)


vi [https://www.leadcoalition.org](https://www.leadcoalition.org) Leaders Engaged on Alzheimer’s Disease (the LEAD Coalition) is a diverse national coalition of member organizations including patient advocacy and voluntary health non-profits, philanthropies and foundations, trade and professional associations, academic research and clinical institutions, and home and residential care providers, large health systems, and biotechnology and pharmaceutical companies. The LEAD Coalition works collaboratively to focus the nation’s strategic attention on dementia in all its causes -- including Alzheimer’s disease, vascular disease, Lewy body dementia, frontotemporal degeneration and Creutzfeldt-Jakob disease -- and to accelerate transformational progress in detection and diagnosis, care and support, and research leading to prevention, effective treatment and eventual cure. One or more participants may have a financial interest in the subjects addressed.